Parkinson's Disease Management
DOI:
https://doi.org/10.34024/rnc.1999.v7.8966Keywords:
Doença de Parkinson, levodopa, complicações motorasAbstract
Levodopa remains the mainstay in Parkinson's disease treatment, although long-term problems may emerge with continuous use. In early symptoms, selegiline, anticholinergic drugs and amantedine are preferred. When symptoms are more proeminent but not incapacitating, dopaminergic agonists can be prescribed. Levodopa therapy is indicated when other drugs no longer provide satisfactory control of symptoms or are not tolerated by the patient. Adding dopaminergic agonists to treatment is a wise measure if higher dosis of levodopa is required. Dietetic orientation, fractioning of the dosis and dopaminergic agonists are necessary in fluctuating and dyskinetic patients. Surgical approach, such as thalamotomy and pallidotomy, are only indicated if non-invasive measures were ineffective.
Metrics
References
Lang AE & Lozano AM. Medical progress: Parkinson's disease. Part 2. N Engl J Med, 339: 1144-1153, 1998.
Poewe W, Wenning G. Levodopa in Parkinson's disease: mechanisms of action and pathophysiology of late failure. In: Jankovic J, Tolosa E (eds). Parkinson's disease and movement disorders. Baltimore, William & Wilkins, 177-190, 1998.
Jankovic J, Marsden CD. Therapeutic strategies in Parkinson's disease. In: Jankovic J, Tolosa E (eds). Parkinson's disease and movement disorders. Baltimore, William & Wilkins, 191-220, 1998.
Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med, 328: 176-183, 1993.
Shannon KM, Bennet Jr JP, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology, 49: 724-728, 1997.
Lees AJ, Head J, Bem-Schlomo Y. Selegiline and mortality in Parkinson's disease: another view. Ann Neurol, 41: 282-283, 1997.
Ferraz HB, Azevedo-Silva SMC, Borges V et al. Apomorfina. Uma alternativa no controle das flutuações motoras da doença de Parkinson. Arq Neuropsiquiatr, 53: 245-251, 1995.
Lieberman A, Ranhosky A. Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology, 49: 162-168, 1997.
Rocha MSG, Andrade LAF, Ferraz HB, Borges V. Discinesias induzidas por levodopa em 176 pacientes com doença de Parkinson. Arq Neuropsiquiatr, 53: 737-742, 1995.
De Angelis EC, Moult, LF, Ferraz H8 at al. Effect of voice rehabilitation on oral communication of Parkinson's disease patients. Acta Neurol Scand, 96: 199-205, 1997.
Ferraz FP, Aguiar PMC, Ferraz HB et al. Talamotomia e pal idotomia estereotáxica com planejamento computadorizado no tratamento da doença de Parkinson. Avaliação do desempenho motor a curto prazo de 50 pacientes. Arq Neuropsiquiatr, 56: 789-797, 1998.
Lang AE, Lozano A. Montgomery E at al. Posteroventral medial pallidotomy in advanced Parkinson's disease. N Engl J Med, 337: 1036-1042, 1997.
Limousin P, Krack R Pollak P et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med, 339: 1105-1109, 1998.
